Core Viewpoint - AnorTech Inc. has granted incentive stock options to directors, employees, and consultants, allowing the purchase of a total of 5,150,000 shares at a price of $0.10 per share [1] Summary by Category Stock Options - The total number of shares for the stock options granted is 5,150,000 [1] - The exercise price for the options is set at $0.10 per share [1] - The options will vest over a period of 18 months and have a term of five years [1] Regulatory Compliance - The stock options are subject to the policies of the TSX Venture Exchange [1]

Core Insights - Abivax has presented new preclinical and clinical data for obefazimod, demonstrating its anti-fibrotic potential and favorable safety profile for treating inflammatory bowel disease at ECCO 2026 [2][3] Group 1: Clinical Data and Efficacy - The data presented includes evidence of obefazimod's anti-fibrotic effects in both preclinical human fibroblast models and in vivo animal models, indicating its potential to address unmet needs in Crohn's disease [4] - A pooled analysis from the Phase 3 ABTECT induction trials shows that obefazimod leads to symptomatic response as early as week 1 and symptomatic remission by week 2, with a nominally significant p-value of <0.05 [4][5] - Obefazimod demonstrated a ~50% reduction in a biomarker of active fibrosis (Pro-C3) and a ~30% reduction in a fibroblast activation marker (⍺SMA) in preclinical models, both with p-values <0.0001 [5] Group 2: Safety Profile - The safety data from the ABTECT-1 and ABTECT-2 trials indicate that the rates of serious treatment emergent adverse events (TEAEs) were comparable across treatment groups, with Obe-50mg at 3.1%, Obe-25mg at 2.2%, and placebo at 3.2% [8] - TEAEs leading to study discontinuation were also similar across groups, with Obe-50mg at 4.7%, Obe-25mg at 1.9%, and placebo at 4.1% [8] Group 3: Mechanism of Action - Biomarker data from the trials indicate that obefazimod enhances the expression of miR-124 and reduces key inflammatory cytokines IL-17A and IL-6 towards homeostatic levels, supporting its mechanism of action in restoring immune balance [4][8] - The mechanism allows for partial reduction of inflammatory cytokines without completely blocking these pathways, which may be beneficial for long-term disease management [8]

Core Viewpoint - Rakovina Therapeutics Inc. has announced an upsized financing plan totaling approximately $2 million, which includes a convertible debenture and a common share private placement to support near-term operations [1][4]. Financing Details - The financing consists of a non-brokered private placement of an unsecured convertible debenture for $1.0 million, along with two million common share purchase warrants, with each warrant exercisable at $0.20 per share until January 28, 2029 [2][9]. - Concurrently, the company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share, aiming for additional gross proceeds of up to approximately $1.0 million [3]. Use of Proceeds - The aggregate gross proceeds from the private placements will be utilized for near-term working capital to support ongoing corporate activities and strategic initiatives while evaluating longer-term financing alternatives [4]. Regulatory Approvals - The closing of the private placements is contingent upon obtaining all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically targeting the DNA-damage response [6][7].

Core Insights - VERSES AI Inc. has filed its Quarterly Report on Form 10-Q for the three and nine months ended December 31, 2025, with the SEC [1] - The company will review its results during an earnings call scheduled for February 24, 2026, at 1:00 PM Eastern time [2][3] Company Overview - VERSES is a cognitive computing company focused on developing next-generation agentic software systems inspired by Nature [3] - The flagship product, Genius™, is designed to provide reliable domain-specific predictions and decisions under uncertainty [3] Conference Call Details - The earnings call will be accessible live over the Internet via the company's website, with listeners advised to prepare 15 minutes in advance [3]

Core Viewpoint - K2 Capital Acquisition Corp. announced that starting February 25, 2026, holders of its 13,800,000 units from the initial public offering can separately trade Class A ordinary shares and rights included in the units [1] Group 1: Offering Details - The units were offered in an underwritten offering, with D. Boral Capital acting as the sole book-running manager [2] - A registration statement on Form S-1 was declared effective by the SEC on January 28, 2026, and the offering is made only by means of a prospectus [2] Group 2: Trading Information - Units not separated will continue to trade on NASDAQ under the symbol "KTWOU," while separated Class A ordinary shares and rights will trade under the symbols "KTWO" and "KTWOR," respectively [1] - Holders must contact the Company's transfer agent, VStock Transfer, to separate their units into Class A ordinary shares and rights [1] Group 3: Company Overview - K2 Capital Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [4]

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (“Helios Fairfax”) (TSX: HFPC.U) announces that it has closed an amendment and restatement of its existing credit facility with FirstRand Bank Limited (acting through its Rand Merchant Bank division) (the “Amended Credit Facility”). The key modifications to the Amended Credit Facility include the following: Facility Increase: The lenders have in ...

Core Viewpoint - Psyence Biomedical Ltd. is advancing its strategic relationship with Psyence Labs Ltd. through the exercise of a put option agreement, which involves an equity investment in PsyLabs to enhance its supply strategy for pharmaceutical-grade psychedelic compounds [1][3][7]. Transaction Overview - Psyence BioMed will acquire equity securities of PsyLabs at a fair market value, with the investment expected to strengthen the strategic alignment between the two companies [3][4]. - The Share-for-Share Exchange will involve PsyLabs issuing 2,900 shares valued at US$5,000,000, while Psyence BioMed will issue 1,146,159 common shares based on a 30-day VWAP of US$4.36 per share [5][6]. - No cash will be exchanged in this transaction, and following the issuance of shares, PsyLabs will own approximately 49.98% of Psyence BioMed's outstanding common shares [6][5]. Strategic Context - The exercise of the put option is seen as a step towards securing high-quality manufacturing capabilities while maintaining capital allocation discipline as Psyence BioMed's development programs progress [7]. Governance - A Special Committee of independent directors reviewed and ratified the transaction, considering the commercial rationale and an independent valuation of PsyLabs [8]. About PsyLabs - PsyLabs is a federally licensed company specializing in the development of psychedelic Active Pharmaceutical Ingredients (APIs), including psilocybin and ibogaine, and has successfully exported products to various countries [9][10]. - The company operates from an ISO 22000-certified facility, ensuring high safety and traceability standards [11]. About Psyence BioMed - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psychedelic therapeutics, specifically psilocybin and ibogaine, to address unmet mental health needs [11].

Core Viewpoint - Constellation Software Inc. has announced a change in the date and time for its fourth quarter conference call, which will now take place on March 9, 2026, at 8:30 am [1]. Group 1: Conference Call Details - The quarterly results will be released via press release and will be available on the company's website and SEDAR+ at 7:00 am EST on March 9, 2026 [2]. - Key executives, including Mark Miller (President), Jamal Baksh (Chief Financial Officer), and Bernard Anzarouth (Chief Investment Officer), will be present during the conference call to address questions regarding the company's results [2]. - To access the call, participants can dial 1-877-879-1183 (North America toll free) or 1-412-902-6703 (International) using conference ID 8822692 [3]. Group 2: Company Overview - Constellation Software Inc. specializes in acquiring, managing, and building vertical market software businesses [4].

Core Viewpoint - Equinox Gold Corp. has filed its audited financial statements and management's discussion for the year ended December 31, 2025, indicating a commitment to transparency and regulatory compliance [1]. Financial Statements - The financial documents are available for download on SEDAR+, EDGAR, and the company's website, providing stakeholders with access to detailed financial performance data [1]. Contact Information - The company has provided contact details for inquiries, including Ryan King, EVP of Capital Markets, with a direct phone number and email addresses for investor relations [2].

Company Overview - Andrew Peller Limited is one of Canada's leading producers and marketers of quality wines and craft beverage alcohol products [2] - The company offers a range of premium and ultra-premium brands, including Peller Estates, Trius, and Wayne Gretzky, among others [2] - It operates 101 independent retail locations in Ontario under various store names [2] - The company also imports and markets premium wines globally through its Andrew Peller Import Agency and The Small Winemaker's Collection Inc. [2] - Additionally, it produces personal winemaking products through its subsidiary, Global Vintners Inc. [2] Recent Developments - W. James Westlake has resigned from the Company's board of directors to focus on other commitments [1] - The Company expressed gratitude for Mr. Westlake's service and wished him well in his future endeavors [1]